We are live on ! Find out more
MREO

Mereo BioPharma
MREO

58 hedge funds and large institutions have $43M invested in Mereo BioPharma in 2023 Q1 according to their latest regulatory filings, with 7 funds opening new positions, 15 increasing their positions, 14 reducing their positions, and 10 closing their positions.

New
Increased
Maintained
Reduced
Closed

7% more repeat investments, than reductions

Existing positions increased: 15 | Existing positions reduced: 14

0.12% less ownership

Funds ownership: 9.85% → 9.73% (-0.12%)

5% less funds holding

Funds holding: 61 → 58 (-3)

7% less capital invested

Capital invested by funds: $46.2M → $43M (-$3.16M)

30% less first-time investments, than exits

New positions opened: 7 | Existing positions closed: 10

Holders
58
Holders Change
-3
Holders Change %
-4.92%
% of All Funds
0.92%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
7
Increased
15
Reduced
14
Closed
10
Calls
$54K
Puts
–
Net Calls
+$54K
Net Calls Change
+$48K

Top Buyers

Rank Fund Capital Flow
1
6CM
683 Capital Management
New York
+$1.69M
2
Millennium Management
Millennium Management
New York
+$1.07M
3
Citigroup
Citigroup
New York
+$1.02M
4
BFM
Boothbay Fund Management
New York
+$385K
5
JGC
J. Goldman & Co
New York
+$267K

Top Sellers

Rank Fund Capital Flow
1
O
OrbiMed
New York
-$2.57M
2
AG
Artal Group
Luxembourg
-$1.13M
3
OCA
Octagon Capital Advisors
New York
-$750K
4
MAM
Monaco Asset Management
Monaco
-$660K
5
Renaissance Technologies
Renaissance Technologies
New York
-$307K
Name Holding Trade Value Shares
Change 		Change in
Stake
RCMNY
1
Rubric Capital Management (New York)
New York
$7.33M – – –
O
2
OrbiMed
New York
$5.48M -$2.57M -2,857,631 -27%
SCM
3
Suvretta Capital Management
New York
$5.21M – – –
RSCM
4
Rock Springs Capital Management
Maryland
$4.41M – – –
Citadel Advisors
5
Citadel Advisors
Florida
$2.15M -$12.9K -14,372 -0.5%
Millennium Management
6
Millennium Management
New York
$1.77M +$1.07M +1,194,281 +91%
TC
7
Tejara Capital
United Kingdom
$1.72M +$222K +247,200 +11%
Alkeon Capital Management
8
Alkeon Capital Management
New York
$1.69M +$225K +250,000 +12%
Goldman Sachs
9
Goldman Sachs
New York
$1.6M -$28.8K -31,981 -1%
BC
10
Boxer Capital
California
$1.59M – – –
CC
11
Clearline Capital
New York
$1.45M – – –
6CM
12
683 Capital Management
New York
$1.41M +$1.69M +1,875,000 +1,500%
TCM
13
Tekla Capital Management
Massachusetts
$1.1M – – –
MAM
14
Monaco Asset Management
Monaco
$930K -$660K -733,416 -36%
Citigroup
15
Citigroup
New York
$799K +$1.02M +1,129,103 +72,987%
DCM
16
DAFNA Capital Management
California
$775K – – –
Renaissance Technologies
17
Renaissance Technologies
New York
$647K -$307K -341,460 -27%
JGC
18
J. Goldman & Co
New York
$429K +$267K +297,000 +96%
BFM
19
Boothbay Fund Management
New York
$302K +$385K +427,403 New
JP Morgan Chase
20
JP Morgan Chase
New York
$302K +$254K +281,874 +194%
TI
21
Tidal Investments
Wisconsin
$235K +$16.9K +18,786 +6%
FAM
22
Formidable Asset Management
Ohio
$234K +$39.4K +43,834 +15%
Primecap Management
23
Primecap Management
California
$210K -$630 -700 -0.2%
Barclays
24
Barclays
United Kingdom
$134K +$21K +23,366 +14%
Acadian Asset Management
25
Acadian Asset Management
Massachusetts
$134K +$173K +191,899 New
1
2 3

MREO Hedge Fund Activity: Q1 2023 in Review

58 of the 6,275 institutional investors tracked by Wall St. Rank reported a position in Mereo BioPharma (MREO) for Q1 2023, worth a combined $43M — down 6.8% from $46.2M a quarter earlier.

Sellers outnumbered buyers: 10 funds closed out of MREO and 7 opened new positions — a net loss of 3 holders — while 14 trimmed existing stakes and 15 added.

The largest buyer was 683 Capital Management, adding an estimated $1.69M. The largest seller was OrbiMed, cutting an estimated $2.57M.

  • 58 institutional investors held Mereo BioPharma (MREO) as of Q1 2023, down from 61 in Q4 2022.
  • Funds reported $43M of Mereo BioPharma stock for Q1 2023, down 6.8% quarter-over-quarter.
  • 7 funds opened new Mereo BioPharma positions in Q1 2023 and 10 closed out, a net change of -3 holders.
  • The largest Mereo BioPharma buyer in Q1 2023 was 683 Capital Management, an estimated $1.69M added.
  • The largest Mereo BioPharma seller in Q1 2023 was OrbiMed, an estimated $2.57M sold.

Based on aggregated 13F filings for Q1 2023.